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Implications for the domain arrangement of axonin-1 derived
from the mapping of its NgCAM binding site
Abstract
The neuronal cell adhesion molecule axonin-1 is composed of six immunoglobulin and four fibronectin
type III domains. Axonin-1 promotes neurite outgrowth, when presented as a substratum for neurons in
vitro, via a neuronal receptor that has been identified as the neuron-glia cell adhesion molecule,
NgCAM, based on the blocking effect of polyclonal antibodies directed to NgCAM. Here we report the
identification of axonin-1 domains involved in NgCAM binding. NgCAM-conjugated microspheres
were tested for binding to COS cells expressing domain deletion mutants of axonin-1. In addition,
monoclonal antibodies directed to axonin-1 were assessed for their ability to block the
axonin-1-NgCAM interaction, and their epitopes were mapped using the domain deletion mutants. The
results suggest that the four amino-terminal immunoglobulin domains of axonin-1 form a domain
conglomerate which is necessary and sufficient for NgCAM binding. Surprisingly, NgCAM binding to
membrane-bound axonin-1 was increased strongly by deletion of the fifth or sixth immunoglobulin
domains of axonin-1. Based on these results and on negative staining electron microscopy, we propose a
horseshoe-shaped domain arrangement of axonin-1 that obscures the NgCAM binding site. Neurite
outgrowth studies with truncated forms of axonin-1 show that axonin-1 is a neurite
outgrowth-promoting substratum in the absence of the NgCAM binding site.
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The neuronal cell adhesion molecule axonin-1 is com-
posed of six immunoglobulin and four fibronectin type
III domains. Axonin-1 promotes neurite outgrowth,
when presented as a substratum for neurons in vitro,
via a neuronal receptor that has been identified as the
neuron-glia cell adhesion molecule, NgCAM, based on
the blocking effect of polyclonal antibodies directed to
NgCAM. Here we report the identification of axonin-1
domains involved in NgCAM binding. NgCAM-conjug-
ated microspheres were tested for binding to COS cells
expressing domain deletion mutants of axonin-1. In
addition, monoclonal antibodies directed to axonin-1
were assessed for their ability to block the axonin-1-
NgCAM interaction, and their epitopes were mapped
using the domain deletion mutants. The results suggest
that the four amino-terminal immunoglobulin domains
of axonin-1 form a domain conglomerate which is
necessary and sufficient for NgCAM binding. Surpris-
ingly, NgCAM binding to membrane-bound axonin-1
was increased strongly by deletion of the fifth or sixth
immunoglobulin domains of axonin-1. Based on these
results and on negative staining electron microscopy,
we propose a horseshoe-shaped domain arrangement
of axonin-1 that obscures the NgCAM binding site.
Neurite outgrowth studies with truncated forms of
axonin-1 show that axonin-1 is a neurite outgrowth-
promoting substratum in the absence of the NgCAM
binding site.
Keywords: axonin- 1/domain arrangement/immunoglobulin
superfamily/neuronal cell adhesion molecules/NgCAM
Introduction
The formation of a complex network of neurons during
the development of the nervous system is based on specific
interactions amongst neurons and between neurons and
their environment. These interactions are likely to be
mediated by surface glycoproteins present on the axons'
leading tip, the growth cone, acting as specific recognition
molecules to guide axons to their targets (Patterson, 1992;
Goodman and Shatz, 1993). Among the presently known
molecules considered to be involved in axon guidance,
neural surface glycoproteins of the immunoglobulin (Ig)
superfamily play a prominent role. These have been
categorized into molecules composed of Ig domains only
or of Ig domains in conjunction with fibronectin type III
(FNIII) domains (Rathjen and Jessell, 1991). Based on
structural criteria, i.e. membrane anchorage and particular
combinations of Ig and FNIII domains, the family of Ig/
FNIII neural glycoproteins can be divided further into
several subgroups (Vielmetter et al., 1994). The glycosyl-
phosphatidylinositol (GPI)-anchored proteins contactin/
F 11/F3, TAG-1/axonin- 1, PANG/BIG-I and BIG-2 consti-
tute one such subgroup and are striking particularly
in their spatially and temporally restricted patterns of
expression during neuronal development (Ranscht, 1988;
Brummendorf et al., 1989; Gennarini et al., 1989; Furley
et al., 1990; Zuellig et al., 1992; Connelly et al., 1994;
Yoshihara et al., 1994, 1995). They are composed of six
Ig and four FNIII domains separated by a glycine/proline-
rich segment. Their modular assembly suggests that the
GPI-anchored Ig/FNIII neural glycoproteins regulate
axonal elongation along specific pathways by multiple
macromolecular interactions (Sonderegger and Rathjen,
1992), and, indeed, several specific binding activities
have now been demonstrated in vitro (Brummendorf and
Rathjen, 1993). Axonin-1 of the chick has been shown to
bind homophilically (Rader et al., 1993) and heterophilic-
ally to neuron-glia cell adhesion molecule (NgCAM;
Kuhn et al., 1991) and Ng-CAM-related cell adhesion
molecule (NrCAM/Bravo; Suter et al., 1995). Both
NgCAM and NrCAM/Bravo belong to a subgroup of Igl
FNIII neural glycoproteins which are composed of six Ig
and five FNIII domains, a single transmembrane segment
and a cytoplasmic tail (Burgoon et al., 1991; Grumet
et al., 1991; Kayyem et al., 1992). The recent description
of axonin-1, NgCAM and NrCAM/Bravo as the molecules
involved in the pathfinding decision of spinal commissural
axons at the floor plate (Stoeckli and Landmesser, 1995)
puts these molecules in the focus of current interest as
one of the best described pathfinding models in vertebrates.
The interaction of axonin- 1 and NgCAM was concluded
to mediate the promotion of neurite outgrowth of chicken
embryonic dorsal root ganglion neurons on axonin- 1
substratum in vitro, as evidenced by the virtually complete
arrest of neurite outgrowth in the presence of polyclonal
antibodies directed to NgCAM (Kuhn et al., 1991). To
understand better the functional implications of this inter-
action, we have begun a detailed structure/function analysis
of axonin-1-NgCAM binding. Here we report the identi-
fication of the NgCAM binding site on axonin- 1 and
propose a model for the domain arrangement of axonin- 1.
With this structure, membrane-bound axonin- 1 may inter-
act with NgCAM of the same membrane rather than with
NgCAM of an apposed membrane. Thus, it is unlikely
that NgCAM is the growth cone receptor for neurite
outgrowth on axonin- 1 substratum. Neurite outgrowth
studies support this prediction.
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Results
The deletion of the fifth and the sixth Ig domain of
axonin-1 results in an increased binding of NgCAM
Entire domains of axonin- 1, as defined by their homology
to the Ig constant domains or the type III domains of
fibronectin (Zuellig et al., 1992) and by exon-intron
borders of the axonin-l gene (Giger et al., 1995), were
deleted by oligonucleotide-directed mutagenesis and
cloned into the axonin- 1 expression vector pSCT-axonin- 1.
Vectors carrying these constructs were introduced into
COS cells by electroporation. The transiently transfected
cells were solubilized 2 days after transfection, and ana-
lysed for axonin- expression by immunoblotting. The
sizes of the axonin- domain deletion mutants were in
agreement with the predicted values (Figure 1). No
axonin- 1 immunoreactivity was detectable on parental
COS cells. Immunofluorescence analyses revealed that all
mutants, except the one where the most amino-terminal
Ig domain was deleted, designated AIgl, were expressed
on the surface of COS cells in similar quantities to wild-
type axonin-l (data not shown). AIgi, although apparently
absent from the cell surface, was detected in similar
quantities to wild-type axonin-1 when solubilized mem-
branes were analysed by immunoblotting (Figure IA),
suggesting that AIgl was produced but remained inside
the cell. Treatment with phosphatidylinositol-specific
phospholipase C revealed a GPI anchorage of axonin-1
heterologously expressed by COS cells (data not shown).
Usually 20-30% of the cells expressed heterologous
protein after transfection by electroporation. Two days
after transfection, cells were incubated with NgCAM-
conjugated polystyrene microspheres (Covaspheres) and,
after washing and fixation, axonin- 1-expressing cells were
identified by indirect immunofluorescence staining. An
initial series of axonin- 1 domain deletion mutants included
the complete set of single domain deletions and three
double domain deletions in the amino-proximal region
(Figure 2A). The NgCAM binding properties of these
mutants together with wild-type axonin-1 are summarized
in Figure 2B. Surprisingly, wild-type axonin-1 expressed
on the surface of COS cells was found to bind NgCAM-
conjugated Covaspheres only weakly. The same result
was obtained with wild-type axonin- 1 heterologously
expressed on the surface of myeloma and fibroblasts cell
lines (data not shown), and was in striking contrast to the
results of Covaspheres aggregation assays where a strong
interaction of native or recombinant axonin- 1 and NgCAM
had been detected with both binding partners covalently
coupled to Covaspheres (Kuhn et al., 1991; Rader et al.,
1993). These findings suggested that the failure of recom-
binant membrane-bound axonin- 1 to interact with NgCAM
may not be ascribed to its heterologous expression but,
probably, to a difference in the accessibility of the NgCAM
binding site of axonin- 1 when covalently coupled to
Covaspheres compared with when membrane-bound. The
NgCAM binding properties of the axonin- domain dele-
tion mutants supported this view. Whereas cells expressing
AIg 12, AIg2, AIg23, AIg3, AIg34, AIg4, AFn2 and AFn3 did
not bind NgCAM-conjugated Covaspheres, transfectants
expressing AIg5 and AIg6 exhibited a strongly increased
NgCAM binding when compared with cells transfected
with wild-type axonin-1 (Figure 2B). To a lesser degree,
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Fig. 1. Size analysis of wild-type axonin-l and axonin-l domain
deletion mutants of transiently transfected COS cells. Solubilized
membranes of non-transfected COS cells ('COS') and COS cells
transfected with wild-type axonin- 1 ('wild-type recombinant') or
domain deletion mutants of axonin- 1 (for labels see Figure 2) were
subjected to SDS-PAGE (7.5%), electrotransferred to nitrocellulose
and immunostained with a mixture of four anti-axonin- 1 mAbs
followed by peroxidase-conjugated secondary antibodies. The epitopes
of the four mAbs used for immunostaining had been mapped to sites
beyond (A) or within (B) the four amino-terminal Ig domains of
axonin-l. Vitreous fluid of 14-day-old chicken embryos ('wild-type
native') was blotted for comparison. Numbers on the edge indicate the
molecular masses of marker proteins in kDa.
AFn4 also was found to exhibit increased NgCAM binding.
No difference between AFnl and wild-type axonin- 1 was
detected. These results suggest that the presence of Ig5
and Ig6 in axonin- 1 somehow masks the NgCAM binding
site of membrane-bound axonin- 1.
The four amino-terminal Ig domains of axonin-1
are necessary and sufficient for NgCAM binding
To localize the NgCAM binding site we exploited the
apparent unmasking of this site exhibited by Ig5 and Ig6
deletion mutants. In a second series of domain deletion
mutants (Figure 3A), double domain deletions were con-
structed by combining each single domain deletion with
2057
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Fig. 2. NgCAM binding by wild-type axonin- 1 and the initial series of axonin- 1 domain deletion mutants. (A) The initial series of axonin- 1 domain
deletion mutants. Coding regions of wild-type axonin-l and domain deletion mutants are drawn schematically. Amino-termini are on the left ('N'),
and carboxy-termini with post-translationally attached GPI anchors are on the right ('GPI'). Ig and FNIII domains are presented as open and solid
ellipses, respectively, and are numbered from the amino- to the carboxy-terminus. Lines indicate domain deletions. The names of mutants indicate
the domains that are deleted, e.g. in AIgl2 the two amino-terminal domains of axonin-l were excised. (B) COS cells expressing wild-type or mutant
axonin-l were identified, after binding of NgCAM-conjugated TRITC Covaspheres and fixation, by indirect immunofluorescence using polyclonal
antibodies to axonin-l and a secondary FITC-conjugated antibody. For each mutant, 100 green fluorescing cells were analysed. Green fluorescing
cells that had bound at least three red fluorescing Covaspheres were scored as binding cells. The analysis of unstained cells revealed a background of
0.1 Covaspheres/cell. Columns represent the mean of two independent experiments (error bars indicate SD). Because of its low surface expression,
the mutant AIgl could not be compared (indicated by *). Note the increased NgCAM binding of mutants AIg5, AIg6 and AFn4 compared with wild-
type axonin- 1.
AIgS and AIg6, respectively. Again, the expression level
of all mutants except the low-expressing AIg5 1 and AIg61
transfectants was found to be similar to wild-type axonin- 1
(data not shown). The NgCAM binding properties of the
second series of axonin- 1 mutants are summarized in
Figure 3B. Loss of NgCAM binding was detected when
AIg2, AIg3 or AIg4 were combined with AIg5 or AIg6.
Although surface expression was low in most cells, a
small percentage of AIgS1 and AIg61 transfectants were
found to have a comparable expression level. These
cells also did not bind NgCAM Covaspheres. In striking
contrast, all combinations of AIgS and AIg6 with deletions
of the FNIII domains were found to exhibit NgCAM
binding as strong as AIgS and AIg6 alone. Likewise, the
double deletion of IgS and Ig6, designated AIg56, showed
no difference in NgCAM binding compared with the
single deletions. These results strongly suggest that the
NgCAM binding site resides in the four amino-terminal
Ig domains of axonin-1. For confirmation, two additional
axonin-1 mutants were constructed (Figure 4). Ig1234
coupled the four amino-terminal Ig domains directly to
the GPI anchor, and AIg 1234 was complementary in
having these same four domains deleted. Whereas no
NgCAM binding was found in the case of AIgi 234,
Ig1234 exhibited strong binding in the same range as AIg5
and AIg6 (Figure 4). This finding demonstrated the four
amino-terminal Ig domains of axonin-1 to be sufficient
for NgCAM binding. In addition, it implies that the
entirety of these domains is necessary forNgCAM binding:
As shown in Figure 3B, all domain deletions involving
Ig 1, Ig2, Ig3 and Ig4 resulted in a complete loss of
NgCAM binding. For further confirmation, single domains
of the axonin- 1 mutant Ig1234 were excised. The resulting
mutants, designated Ig234, Ig 134, Ig124 and Ig 123, were
found to have lost the NgCAM binding property of Igi 234
completely (data not shown). Clearly, the four amino-
terminal Ig domains of axonin- I were found to be neces-
sary and sufficient for NgCAM binding.
The NgCAM binding properties of axonin- 1
suggest a backfolded shape which is supported
by electron microscopy
The finding that the four amino-terminal Ig domains
directly coupled to the GPI anchor exhibit markedly
increased NgCAM binding as compared with wild-type
axonin- 1 (Figures 2 and 4) supports the suggestion that
the presence of Ig5 and Ig6 masks the NgCAM binding
site. This feature of membrane-bound axonin- 1 could be
explained by a backfolded shape: the amino-terminal
NgCAM binding site folds back towards the membrane
and becomes masked by parts of the axonin-1 structure
beyond the four amino-terminal Ig domains, namely IgS
and Ig6. The predicted overall shape of axonin- I was
confirmed by electron microscopy of native axonin- 1
molecules (Figure 5). Electron micrographs of negatively
stained axonin- 1 molecules showed exclusively horseshoe-
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Fig. 3. NgCAM binding by the second series of axonin- domain deletion mutants. (A) Double domain deletions were constructed by combining
each single domain deletion outlined in Figure 2 with AIg5 and AIg6, respectively. For symbols and labels see Figure 2. (B) The Covaspheres
binding assay was performed and evaluated as described for Figure 2. Solid and open columns refer to double domain deletions on the basis of AIg5
and AIg6, respectively; the hatched column refers to the double domain deletion AIg56. Columns represent the mean of two independent experiments
(error bars indicate SD). Because of their low surface expression, mutants AIg5l and AIg6l were not taken into consideration (indicated by *);
however, no NgCAM binding was detected in the small percentage of cells with a comparable expression level.
shaped structures, the uniform appearance suggesting little
segmental flexibility. The size of each arm of the horseshoe
was lOx4 nm and the distance between the arms was
-5 nm (data not shown). As known from crystallographic
data, the dimensions of a single Ig or FNIII domain are
~4X2.5X2 nm (Amzel and Poljak, 1979; Leahy et al.,
1992). Thus, the size of the horseshoe-shaped structures
is large enough to comprise the 10 modules of one
axonin- 1 molecule, but too small to allow the interpretation
of these structures as axonin-1 dimers. In addition, we
proved by sedimentation equilibrium ultracentrifugation
that soluble axonin- molecules do not form aggregates
below a concentration of 10 mg/ml (data not shown),
while the electron microscopy data are based on an
axonin- 1 concentration of 75 gg/ml. The horseshoe-shaped
structure of axonin- as revealed by electron microscopy
is in good agreement with the backfolded shape proposed
on the basis of the NgCAM binding properties of the
axonin- domain deletion mutants.
The four amino-terminal domains of axonin- 1 form
a domain conglomerate
The whole of the four amino-terminal Ig domains was
found to be required for NgCAM binding. As a result,
deletion analyses within this region do not allow the
localization of the actual binding site. To obtain indepen-
dent data to extend this mapping analysis, a selection of
13 monoclonal antibodies (mAbs) directed to axonin-1
was included in the binding assays. Based on axonin-1
deletion mutants and indirect immunofluorescence ana-
lyses, eight mAbs, namely V3B3, X7F6, X7H5, X3G12,
X7G9, V9H6, X9C12 and X9H8, had been mapped to the
four amino-terminal Ig domains (Table I). The epitopes
of the remaining five mAbs VIF1, X9A1 1, X9B10, X9A9
and X9C3 were localized to domains Ig5, Fnl, Fn2,
Fn3 and Fn4, respectively (data not shown). Control
experiments had revealed that none of the selected mAbs
binds NgCAM. The interference of the mAbs with binding
of NgCAM-conjugated Covaspheres to membrane-bound
axonin-1 was investigated based on COS transfectants
transiently expressing the axonin-1 mutant AIg6 (Figure
6A). Two out of 13 mAbs, namely X9H8 and X7F6, were
found to interfere strongly with NgCAM binding. Both
mAbs had been mapped to the four amino-terminal Ig
domains. In contrast, none of the tested mAbs with
epitopes beyond Igl-Ig4 influenced NgCAM binding.
This finding confirmed that the NgCAM binding site of
axonin-1 resides in the four amino-terminal Ig domains.
Figure 6B shows that mAb X9H8 interfered as strongly
with the binding of NgCAM Covaspheres by cells
expressing the axonin-1 mutant AIg6 as polyclonal anti-
bodies raised against axonin-1. In addition, X9H8 also
2059
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Fig. 5. Structure of axonin- 1 as revealed by negative staining electron
microscopy. The upper panel shows a field of axonin- I molecules, and
the bottom row shows a gallery of selected axonin- I molecules at
higher magnification. The uniform appearance of the horseshoe-shaped
structures suggests little segmental flexibility. Bars = 50 nm for upper
panel, 5 nm for bottom row.
algl 234 g91234
Fig. 4. NgCAM binding by the complementary axonin- mutants
AIg1234 and IgI234. For symbols, labels and quantitative analysis see
Figure 2. The solid column indicates NgCAM binding by AIgl234. the
open column that of Ig1234. Columns represent the mean of two
independent experiments (error bars indicate SD).
prevented the interaction of NgCAM with wild-type
axonin-1 and the axonin-1 mutant Ig1234, respectively
(Figures 6B and 7). This indicates that the axonin- 1
mutants with increased NgCAM binding expose the same
NgCAM binding site as that in wild-type axonin-1.
To narrow down further the NgCAM binding site,
epitopes of the eight mAbs that had been mapped to the
four amino-terminal Ig domains were analysed in more
detail. Table I shows that only four out of eight epitopes
could be localized to a single domain, either Igl or Ig4.
One mAb, X7H5, required the presence of two domains,
Igl and Ig4, for binding, and mAb X3G12, mapped to
Ig4, exhibited diminished binding on mutants with a
deletion of Igl, suggesting a close physical association of
Igl and Ig4. The entirety of all four amino-terminal
domains was found to be necessary for the binding of
three mAbs, a binding property strongly resembling that
of NgCAM reported before. The mAb X9H8, found to
interfere with NgCAM binding most potently, belongs to
this latter group. From these data we conclude that a close
physical association of the four amino-terminal Ig domains
exists and that binding of NgCAM requires the whole of
this conglomerate.
The NgCAM binding site of axonin-1 is not
necessary for neurite outgrowth on axonin-1
substratum in vitro
Axonin-I adsorbed to tissue culture plastic was found to
promote neurite outgrowth of cultured embryonic dorsal
root ganglion neurons (Stoeckli et al., 1991). The growth
cone receptor for adsorbed axonin-1 was concluded to be
NgCAM, based on the fact that neurite outgrowth on
axonin-1 was blocked by NgCAM antiserum Fab (Kuhn
et al., 1991). However, a direct interaction between
adsorbed axonin- 1 and growth cone NgCAM was not
shown. At that time, we could not exclude the possibility
that, despite the interaction of axonin-1- and NgCAM-
coated Covaspheres, adsorbed axonin- 1 exerts its neurite
outgrowth-promoting activity via an interaction with a
growth cone receptor other than NgCAM and that anti-
NgCAM Fab perturb this activity more indirectly. The
results presented here suggest that the NgCAM binding
site of membrane-bound axonin-1 is not accessible for
NgCAM of an apposed membrane and prompt a
reconsideration of the assumption that axonin- 1 substratum
exerts its neurite outgrowth-promoting effect by a direct
binding to NgCAM of the growth cone. To address this
point, we analysed the neurite outgrowth activity of native
axonin- 1 coated onto tissue culture plastic and presented
as substratum for dissociated dorsal root ganglion neurons
from 10-day-old chicken embryos in the presence of
monovalent X9H8 antibody. As already shown, X9H8
was found to block the axonin-1-NgCAM interaction
most potently. Although X9H8 Fab bound to adsorbed
axonin-1 (data not shown), no perturbation of neurite
outgrowth was detected (Figure 8C and E). Moreover, no
perturbation of neurite outgrowth was obtained for X7F6
Fab which is also expected to inhibit binding of neuronal
NgCAM to adsorbed axonin- 1 (Figure 6A; data not
shown). In contrast, monovalent polyclonal antibodies
directed to axonin- 1 completely blocked neurite outgrowth
on axonin- 1 (Figure 8E) and, as a control, did not inhibit
neurite outgrowth on laminin (data not shown). These
results suggested that blocking the NgCAM binding site
of adsorbed axonin- 1 does not interfere with its neurite
outgrowth-promoting activity.
In order to confirm this finding, neurite outgrowth was
examined on three different axonin-1 variants produced
in a myeloma-based expression system (Traunecker et al.,
199 la). Previously, we had demonstrated that recombinant
axonin-1 generated by this system is highly similar to
native axonin-1 with respect to both its structural and
2060
80 -
60
40 -
0I)
-a
co
._
20 -
0 -
Mi;
I;ik k's
4,i R
.......
... NU
Domain arrangement of axonin-1
Table 1. Epitope mapping of anti-axonin- mAbs to the four amino-terminal Ig domains
V3B3 X7F6 X7H5 X3G12 X7G9 V9H6 X9C 12 X9H8
Wild-type +±+ ++ ++ +++ +4- ++ ++ ++
AIl1234 - - - - - - -
-
Ig1234 ++ ++ ++ ++ + ++ ++ ++
AIg-2 -4 - - -
AIg2 ++ ++ + ++ ++ - - -
Alg23 ++ ++ + ++ ++ - - -
Alg3 ++ ++ + ++ ++ - - -
AIg3 ++ +± - - - - - -
AzIg4 ++ ++ - _ _ _ _
Epitope IgI Igl Igl/4 Ig4 Ig4 Igl-4 Igl-4 Igl-4
Binding of mAbs to wild-type axonin-l and axonin-l domain deletion mutants expressed on the surface of COS cells was vizualized by
immunofluorescence analysis using FITC-conjugated anti-mouse IgG antibody. Strong immunofluorescence is indicated by ++ weak
immunofluorescence by '+- and no immunofluorescence by -'. In the last row the deduced epitope location is given.
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Fig. 6. Interference of anti-axonin-l mAbs with NgCAM binding. (A) Interference of 13 selected anti-axonin-l mAbs with the binding of NgCAM-
conjugated Covaspheres by axonin- mutant AIg6 transiently expressed on the surface of COS cells. Cells expressing AIg6 were pre-incubated with
IgG of mouse anti-axonin- mAbs that did not bind NgCAM. After binding of NgCAM-conjugated TRITC Covaspheres and fixation, AIg6-
expressing cells that had bound the antibody were visualized by a FITC-conjugated anti-mouse IgG antibody. The first column ('no Ab') indicates
the NgCAM binding of untreated AIg6. The first eight mAbs. namely V3B3, X7F6, X7H5, X3G12. X7G9, V9H6, X9C12 and X9H8, bind to
epitopes located in the four amino-terminal Ig domains of axonin-l (Table I). The epitopes of VIFI, X9All, X9B10. X9A9 and X9C3 were mapped
to the axonin-I domains Ig5, Fnl. Fn2, Fn3 and Fn4. respectively. Quantitative analysis was carried out as described for Figure 2. Columns represent
the mean of two independent experiments (error bars indicate SD). t-test analysis revealed that results obtained with mAbs V3B3, X7H5, X7G9,
V9H6. X9C12. VIFI. X9AI 1. X9B10. X9A9 and X9C3 do not show a significant difference from the control (P>0.05), while results derived from
mAbs X7F6 (P<0.001). X3G12 (P<O.05) and X9H8 (P<0.002) are statistically different from the control. (B) In addition to axonin-l mutant AIg6,
the anti-axonin-l mAb X9H8 also blocked NgCAM binding by wild-type axonin-l and axonin-l mutant IgI234, and is as potent as polyclonal
antibodies to axonin-1. The interference of mAb X9H8 with NgCAM binding of wild-type axonin-I (open columns). AIg6 (solid columns) and
Ig1234 (hatched columns) is shown in comparison with goat polyclonal IgG raised against axonin-l ('antiserum').
functional integrity (Rader et al., 1993). To obtain soluble
axonin- variants, the four amino-terminal Ig domains, a
variant lacking the four amino-terminal Ig domains and
wild-type axonin- 1 were fused to the Ig CK domain of the
mouse Ig light chain to generate Ig 234-CK, AIg 234-C,
and wild-type-C,, respectively (Figure 8A). The soluble
axonin-1 variants were constitutively secreted by trans-
fected J558L myeloma cells, immunoaffinity purified with
an anti-C, mAb, and analysed by SDS-PAGE (Figure
8B). The purified axonin- variants were conjugated to
fluorescent Covaspheres and analysed for their NgCAM
binding capability. As expected, only Covaspheres
conjugated with wild-type-Ct or IgI234-C, but not
AIg1234-C, formed mixed aggregates with NgCAM-
conjugated Covaspheres (data not shown). This result
further confirmed the mapping of the NgCAM binding
site to the four amino-terminal Ig domains of axonin-1
and, in addition, revealed the structural and functional
integrity of the soluble axonin- I-C, fusion products. To
test for neurite outgrowth-promoting activity, the soluble
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Fig. 7. Interference of anti-axonin-I mAb X9H8 with the binding of NgCAM-conjugated Covaspheres by axonin-l mutant Ig1234 expressed on the
surface of transiently transfected COS cells. (A) and (B) COS cells expressing the axonin-1 mutant Ig1234 were detected microscopically after
binding of NgCAM-conjugated TRITC Covaspheres and fixation by indirect immunofluorescence using polyclonal antibodies to axonin-1 and a
secondary FITC-conjugated antibody. (C) and (D) Ig1234-expressing COS cells were pre-incubated with IgG of the mouse anti-axonin-1 mAb
X9H8. After binding of NgCAM-conjugated TRITC Covaspheres and fixation, IgI234-expressing cells that had bound the antibody were detected by
a FITC-conjugated anti-mouse IgG antibody. (A) and (C) Phase contrast optics. (B) and (D) Optics for simultaneous detection of FITC and TRITC
fluorescence. Bar = 100 gm.
axonin- 1 variants were coated onto tissue culture plastic
and presented as substratum for dissociated dorsal root
ganglion neurons from 10-day-old chicken embryos. While
the number of neurons with neurites on wild-type-C,
and AIgl234-C, was comparable with native axonin- 1,
Ig 1 234-CK was found to have strongly reduced outgrowth-
promoting activity in the range of ovalbumin substratum
(Figure 8E). Compared with native axonin- 1, purified by
the four-step chromatographic procedure established by
Ruegg et al. (1989), the neurite length on both wild-type-
CK and AIgl234-CK was slightly lower (data not shown).
We also have observed a reduction of neurite length for
immunoaffinity-purified native and recombinant axonin-1
and ascribe it to the relatively harsh conditions which
have to be used for eluting proteins from immunoaffinity
columns (Rader et al., 1993; data not shown). As for
native axonin-1, neurite outgrowth on wild-type-C,r and
AIgl 234-C, could be inhibited specifically by the presence
of monovalent polyclonal antibodies directed to axonin-1,
whereas addition of X9H8 Fab had no effect (Figure 8E).
Taken together, these data show that the four amino-
terminal Ig domains of axonin- 1 which include the
NgCAM binding site are not necessary for neurite out-
growth on axonin-1 substratum.
Discussion
A domain conglomerate of the four
amino-terminal Ig domains forms the NgCAM
binding site of axonin-1
The localization of the NgCAM binding site of axonin-1
was investigated by a combination of domain deletion
mutants and mAbs. This strategy was in part guided by
structure/function analyses of ICAM-1, a cell adhesion
molecule of the Ig superfamily expressed in the immune
system, in which domain deletion studies had revealed
that individual domains exhibit distinct ligand binding
properties (Staunton et al., 1990; Diamond et al., 1991).
To ensure that domains adjacent to the deletion remained
intact with regard to their primary structure, we have
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Fig. 8. Localization of the neurite outgrowth-promoting segment of axonin- in relation to the NgCAM binding site. (A) Schematic representation of
soluble axonin- variants fused to the Ig CK domain (hatched ellipse). For symbols and labels see Figure 2. (B) The molecules were stably expressed
by myeloma cells, purified from supernatants by affinity chromatography using an anti-C, mAb, and analysed on SDS-PAGE (7.5%) after staining
with Coomassie Blue. Numbers on the right indicate the molecular masses of marker proteins in kDa. The faint staining of an additional protein
band at 66 kDa in the wild-type-C,c preparation presumably represents traces of serum albumin. The faint staining of additional protein bands at -50
kDa in the Igl234-C, preparation represents traces of decomposition products of Igl234-C,c, as demonstrated by immunoblotting (data not shown).
(C) Neurite outgrowth of dissociated chicken embryonic dorsal root ganglion neurons on native axonin-1 substratum in the presence of monovalent
anti-axonin-1 mAb X9H8. After 22 h in culture, the cells were fixed and photographed using phase contrast optics. (D) Neurite outgrowth on
AIgl234-C, substratum. Bar = 50 gim. (E) Quantification of neurite outgrowth. The percentage of cells with neurites longer than two cell body
diameters was determined on native axonin-l (wild-type'), wild-type-Cr, AIgl234-C., Igl234-C, and, as negative control, ovalbumin. Fab of anti-
axonin-1 mAb X9H8 or Fab of axonin-I antiserum were added to a final concentration of 30 or 300 gg/ml, respectively. Columns represent the
mean of two independent experiments (error bars indicate SD).
excised the domains precisely at their borders by oligo-
nucleotide-directed mutagenesis. When the domain dele-
tion mutants were used for the mapping of 100 mAbs
directed to axonin- 1, an unequivocal assignment was
possible for the fifth and sixth Ig domain and the four
FNIII domains. With deletions of the four amino-terminal
Ig domains, however, approximately one half of the mAbs
did not bind if any of the four domains was absent,
whereas the others were localized either to the first or the
fourth but never to the second or third Ig domain (Table
I; data not shown). As the most straightforward interpreta-
tion of these results, we postulate that the first and
the fourth Ig domain can assume a native structure
independently of the presence of the other domains,
whereas the second and the third Ig domain maintain their
spatial structure only within the intact conglomerate. Thus,
the antibodies that recognize only the intact conglomerate,
but not the mutants with deletions of one of the four
amino-terminal domains, are likely to be directed to the
second or third Ig domains.
The binding analyses of NgCAM-conjugated micro-
spheres to axonin-I domain deletion mutants expressed at
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Fig. 9. Model of the domain arrangement of axonin- 1. Based on the finding that a deletion of the fifth and sixth amino-terminal Ig domain of
axonin- 1 results in an increased NgCAM binding, a model for the domain arrangement of axonin- 1 is proposed. By means of the glycine/proline-rich
segment which separates Ig and FNIII parts, the six Ig domains fold back towards the membrane. The four amino-terminal Ig domains (Ig 1, Ig2, Ig3
and Ig4) are shown in close physical association. This conglomerate bears the NgCAM binding site. It is inaccessible to NgCAM presented on either
an opposing cell surface or on Covaspheres (arrow). Mutants having Ig5 and/or Ig6 deleted unmask the NgCAM binding site as shown for the
axonin-l mutants AIg56 and IgI234. When axonin-I is coupled by an amino group-reactive agent to the surface of polystyrene microspheres, the
NgCAM binding site is expected to be surface oriented in at least a fraction of the axonin-1 molecules, explaining the pronounced axonin-l-
NgCAM interaction found with axonin-l- and NgCAM-conjugated Covaspheres (Kuhn et al., 1991).
the surface of COS cells revealed the NgCAM binding
site to reside within the four amino-terminal Ig domains.
The entirety of this substructure was required for NgCAM
binding. Together with the conclusions drawn from the
mAb epitope mapping studies, these results strongly sup-
port the idea that these domains form a domain conglomer-
ate. The blocking effects of two mAbs with defined
binding locations allowed a further localization of the
NgCAM binding site. mAb X9H8, which was found to
interfere most strongly with the NgCAM binding of
axonin- 1, belongs to the group of mAbs that require the
entirety of the amino-terminal domain conglomerate for
binding and, thus, presumably binds to the second or third
Ig domain or to domain borders involving the second or
third Ig domain or both. NgCAM binding also is blocked
by mAb X7F6 which was mapped to the first Ig domain.
Thus, the first and at least one of the two following
domains appear to be involved in the structure of the
NgCAM binding site. Based on domain deletion mutants
and mAb epitope mapping, the NgCAM binding site of
Fl 1, a close relative of axonin-l exhibiting 52.5% amino
acid sequence identity, was mapped to the two amino-
terminal Ig domains (Brummendorf et al., 1993). However,
the smallest Fl1 domain deletion mutant with NgCAM
binding activity included all four amino-terminal Ig
domains. Thus, the entirety of this substructure seems to
be necessary for NgCAM binding by both axonin-1 and
Fl 1. In consideration of these results, it appears likely
that the NgCAM binding sites of axonin-l and Fl1 are
related if not identical.
A model of the domain arrangement of axonin-1
The domain conglomerate of the four amino-terminal Ig
domains was found to be necessary and sufficient for
NgCAM binding. Surprisingly, the construct comprising
these four Ig domains directly coupled to the GPI anchor
exhibited markedly increased binding as compared with
wild-type axonin-1, suggesting that parts of the axonin-1
structure beyond the four amino-terminal Ig domains exert
a strong inhibitory influence on the NgCAM binding
function of the domain conglomerate. Domain deletion
studies in the region distal to the conglomerate identified
the fifth and the sixth Ig domain as crucial for this
inhibitory effect. Strongly increased NgCAM binding was
observed with the single domain deletion mutants AIg5
and AIg6, and with all double domain deletions combining
either AIg5 or AIg6 with single domain deletions beyond
the four amino-terminal Ig domains. Clearly, the weak
binding of NgCAM-conjugated microspheres to mem-
brane-bound axonin-1 correlates with the presence of the
fifth and sixth Ig domain of axonin- 1. Based on these
results and on electron micrographs which suggest a
horseshoe-shaped structure of axonin- 1, we present a
model of the domain arrangement of axonin- 1 (Figure 9).
As a main feature of this model, the six Ig domains,
including a conglomerate of the four amino-terminal Ig
domains, fold back towards the membrane, possibly by
means of the highly conserved glycine/proline-rich seg-
ment between the Ig and the FNIII moieties (Furley et
al., 1990; Zuellig et al., 1992; Hasler et al., 1993). Due to
the backfolding, the amino-terminal domain conglomerate
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containing the NgCAM binding site becomes located close
to the membrane-anchored carboxy-terminal domains and,
thus, may be inaccessible for NgCAM exposed on the
surface of another cell. Conversely, when axonin- 1 is
coupled randomly to microspheres, the NgCAM binding
site is expected to be surface oriented in at least a fraction
of the axonin- 1 molecules (Figure 9), explaining the strong
binding to NgCAM observed in these experiments (Kuhn
et al., 1991; Rader et al., 1993). Bulky and charged sugar
residues located on the fifth and sixth domain might
contribute to the inaccessibility of the NgCAM binding
site of membrane-bound axonin- 1, as suggested by the
fact that four out of eight potential N-glycosylation sites
conserved among axonin- 1 and its mammalian homo-
logues are concentrated on the fifth and sixth Ig domain
(Hasler et al., 1993). In addition to deletions involving
the fifth and sixth Ig domain, domain deletion mutant
AFn4 was found to have increased NgCAM binding
compared with wild-type axonin-1. Assuming a stabiliza-
tion of the backfolded shape by an intramolecular inter-
action near to the membrane, e.g. by a physical association
of the first Ig and the fourth FNIII domain, the increased
NgCAM binding by the axonin- 1 mutant AFn4 could be
ascribed to a destabilization of the backfolded shape
resulting in an improved accessibility of the NgCAM
binding site. A stabilization of the backfolded shape by
an intramolecular interaction of axonin-1 is also suggested
by the electron micrographs. In contrast to NCAM (Becker
et al., 1989) and ICAM-l (Staunton et al., 1990), electron
micrographs of axonin-1 revealed only little segmental
flexibility.
The electron micrographs of axonin- 1 at the presently
available resolution support the backfolded shape but do
not allow a more detailed description of the tertiary
structure of axonin- 1. In particular, it is important to
note that the structural features of the detailed domain
arrangement of axonin-1 as depicted in Figure 9 are based
on the NgCAM binding site mapping by axonin-1 domain
deletion mutants and on the epitope mapping of anti-
axonin-1 mAbs.
A reconsideration of the molecular interaction
involved in neurite outgrowth on axonin-1
substratum
A major conclusion drawn from the membrane-proximal
location of the NgCAM binding site of axonin-1 might
be that axonin-1 and NgCAM interact in the plane of the
same membrane (in cis) rather than across the intermem-
brane space (in trans). This prediction is supported by
several independent observations. (i) When TAG-I and
L 1, the putative rodent homologues of axonin- 1 and
NgCAM, were expressed on the surface of Drosophila
Schneider 2 cells, no interaction in trans occurred, as
indicated by the observation that the cells did not form
mixed aggregates (Felsenfeld et al., 1994). (ii) Evidence
for an interaction of axonin- 1 and NgCAM in cis is
derived from observations of co-clustering (Stoeckli et al,
1993) and cross-linking (S.Kunz and P.Sonderegger, in
preparation) of axonin- 1 and NgCAM in the plane of the
same membrane. (iii) Neurite outgrowth studies in the
presence of anti-axonin- 1 mAbs that interfere with
NgCAM binding and on truncated forms of axonin- 1 show
that the neurite outgrowth-promoting activity of axonin-1
substratum is not mediated by an axonin-I-NgCAM
interaction in trans.
As determined by the neunte outgrowth studies on
truncated forms of axonin-1, the growth cone receptor for
axonin- 1 substratum binds axonin-1 in a region distal to
the four amino-terminal Ig domains that form the NgCAM
binding site. Candidates for this axonin- 1 receptor include
the currently identified axonin-1 ligands, namely axonin-1
itself (Rader et al., 1993) and NrCAM/Bravo (Suter et al.,
1995). In addition, an c43I integrin was reported to be
involved in neurite outgrowth on TAG- I substratum
(Felsenfeld et al., 1994). The fact that polyclonal anti-
bodies directed to L1/NgCAM interfere with neurite out-
growth on TAG-I/axonin-1 substratum (Kuhn et al., 1991;
Felsenfeld et al., 1994) suggests that neuronal LI/NgCAM
is involved in neurite outgrowth on TAG- 1/axonin- 1
substratum. On the one hand, we cannot exclude the
possibility that polyclonal antibodies binding to Lu/
NgCAM trigger an intracellular signal that reverses the
signal induced by TAG-1/axonin-1 substratum; indeed, it
is known that polyclonal and at least one monoclonal
antibody directed to LI are capable of triggering intracellu-
lar signals (Appel et al., 1995). On the other hand, it is
conceivable that neuronal LI/NgCAM is directly involved
in neurite outgrowth on TAG-1/axonin-1 substratum by
an interaction in cis with the neuronal receptor of adsorbed
TAG-1/axonin-1. Networks of molecules interconnected
in the plane of the membrane and across the intermembrane
space have been proposed as powerful means of regulating
the growth and the guidance of axons during neurogenesis
(Sonderegger and Rathjen, 1992). The elucidation of the
domain arrangement and the mapping of the binding sites
of the participating molecules provides a basis for future
investigations of the molecular composition and structure
of these networks.
Materials and methods
Materials
Native axonin-I was purified from the vitreous fluid of 14-day-old
chicken embryos (Ruegg et al., 1989). NgCAM was isolated from 14-
day-old chicken brain membranes by immunoaffinity chromatography
using an anti-NgCAM mAb provided by Dr F.G.Rathjen (Rathjen et al.,
1987). Goat and rabbit polyclonal and mouse monoclonal antibodies
against axonin-1 were raised as previously described (Ruegg et al.,
1989). IgG and Fab were obtained as previously specified (Stoeckli
et al., 199 1).
Construction of axonin-1 deletion mutants
A 2.2 kb Sacl-HindIll fragment, a 1.7 kb EcoRI-HindIll fragment, a
0.6 kb BamHI-HindIII fragment and a 1.1 kb HindIll fragment were
isolated from the axonin-I expression vector pMAX which contains the
entire coding region of the axonin-l cDNA (Rader et al., 1993). The
fragments were cloned into the phagemid vector pTZ19U (Bio-Rad
Laboratories, Richmond, CA) generating pTZI9U/axS-H, pTZ19U/
axE-H, pTZ19U/axB-H and pTZ19U/axH-H, respectively. pTZ19U/axB-
H-H was generated by cloning the 1.1-kb HindIII fragment into pTZ I 9U/
axB-H. Uracil-containing single strand DNA as a template for in vitro
mutagenesis was obtained by using the Escherichia coli strain CJ 236
(Bio-Rad) and the helper phage VCSM1 3 (Stratagene, La Jolla, CA) as
described (Yuckenberg et al., 1991). The 10 single domain deletions
were made by loop-out oligonucleotide-directed mutagenesis using the
following oligonucleotides: CRAIgl, 5'-TCTGGTGCCAAGCACAGA-
GTGGCGGCTl-TTTGCAGGAATTCTCTGCAG-3'; CRAIg2, 5'-GGG-
AAGCATCCCTCCGCTTTGGCGACGCCAGGCAGTATGCACCCAG-
3'; CRAIg3, 5'-CCAGCTCAGCCTGGCTGCCGAGGCTCAGCCGG-
ACTGGCTGGATG-3'; CRAIg4, 5'-TACCAGGGCCGCATCATCATT-
CACGCCTTAGCACCAGATTTTAGACTAAAC-3'; CRAIg5, 5'-CAA-
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GTGCTGAATTAACAGTGCAAGCCGATGCCACCAAAATCACACT-
GGCAC-3'; CRAIg6, 5'-AGCACGGGGATCCTCTCTGTTCGAG-
CCACGCTGACTGTCAGAGGACC-3'; RLAFn 1, 5'-GCCACGCT-
GACTGTCAGAGGACCCACGGTGGCACCATCTGGGCTCGGC-3';
RLAFn2, 5'-CGTACCAAAGAAGCAGCACCCAAGGTGGCACCA-
TTCAGAGTTACGGCCAAAGCC-3'; RLAFn3, 5'-GTGTACTCT-
GCAGAAGAAGAACCAAGGAGGCCACCAGGCAACATCTCC-3';
RLAFn4, 5'-AACATCACGACCACAAAGCCACCAACCAGTATGA-
TGGTGGAAGACTCC-3'.
Oligonucleotide phosphorylation, annealing and second-strand syn-
thesis were performed as described (Yuckenberg et al., 1991) using
pTZl9U/axS-H as a template for CRAIg 1 and CRAIg2, pTZ 19U/axE-H
for CRAIg3, CRAIg4, CRAIgS and CRAIg6, pTZ19U/axB-H-H for
RLAFnl, and pTZ19U/axH-H for RLAFn2, RLAFn3 and RLAFn4. All
other deletions were made by introducing EcoRI sites at different
locations. CREI (5'-AGCTACGGGCCGGAATTCGAGGAGCAGCC-
AGC-3') introduced an EcoRI site in front of the IgI coding region, CRE2
(5'-CTGGCTGCCGAGGAATTCAGGCAGTATGCACC-3') at the Ig2/
Ig3 border, CRE3 (5'-CACGCTCAGCCGGAATTCCTGGATGTGAT-
CACG-3') at the Ig3/Ig4 border, CRE4 (5'-GCTGAATTAACAGTGC-
AAGAATTCGCACCAGATTTTAGAC-3') at the Ig4/Ig5 border and
CRE/GPI (5'-GACCCCAGCAGAATTCCACATCGTCCG-3') between
Fn4 and the sequence responsible for GPI anchorage. In vitro mutagenesis
was performed as described above using pTZ19U/axS-H as a template
for CREl, pTZ19U/axE-H for CRE2, CRE3 and CRE4, and pTZI9U/
axH-H for CRE/GPI. By use of the generated EcoRI sites in addition to
the natural EcoRI site at the Igl/Ig2 border, the deletion mutants AIgl2,
AIg23, AIg34, AIg1234 and Igl234 were generated by depletion of the
respective EcoRI fragments. Due to the EcoRI insertions, the latter
constructs led to conservative amino acid substitutions (see below). All
deletion mutants were verified by double-strand DNA sequencing and
cloned into the expression vector pSCT-axonin- I which drives the
axonin-1 expression under the cytomegalovirus promoter and contains
an SV40 origin of replication. To generate the double deletions AIg51,
AIg52, AIg53, AIg5Fn1, AIg5Fn2, AIg5Fn3, AIg5Fn4, AIg6l, AIg62,
AIg63, AIg64, AIg6Fn2, AIg6Fn3 and AIg6Fn4, single deletions were
combined by substituting appropriate restriction fragments. Neighboured
double domain deletions were generated as follows and verified by
double-strand DNA sequencing: AIg54 by ligation of BclI at the beginning
of the Ig4 coding region to BamHI at the end of IgS using pSCT-axonin-
I produced in the dam- Ecoli strain GM33; AIg56 by ligation of EcoRV
at the beginning of Ig6 to SmaI at the beginning of Fn using pSCT-
axonin-l/Alg5; and AIg6FnI by ligation of SinaI at the beginning of
Fnl to Klenow-treated HindIII at the end of Fnl using pSCT-axonin-
I/AIg6.
Summary of the obtained mutants by their amino acid variation
compared with wild-type axonin- I (Zuellig et al., 1992): AIg I A(M27-
F124);AIg2 = A(F126-E227);AIg3 = A(D228-H319);AIg4 A(A320-
Q408); AIgS = A(L410-R501); AIg6 = A(D502-S594); AFn = A(P603-
P705); AFn2 = A(T706-P807); AFn3 = A(K808-P908); AFn4 =
A(P907-G 1001); AIg 12 = A(M27-F 124; S 131 -A229); AIg23 = A(S 131 -
W324); AIg34 = A(A229-A409), D228E, L41OF; AIg1234 = A(M27-
F124; S13 1-L410); Ig1234 = A(A409-A992), V994F; AIg5l = A(M27-
F124; L410-R501); AIg52 = A(F126-E227; L410-R501); AIg53 =
A(D228-H319; L410-R501); AIg54 = A(T329-G496); AIg56 =
A(L410-R501; 1515-P603); AIg5FnI = A(L410-R501; P603-P705);
AIg5Fn2 = A(L410-R501; T706-P807); AIg5Fn3 = A(L410-R501;
K808-P908); AIg5Fn4 = A(L410-R501; P907-GIO01); AIg6l
A(M27-F124; D502-S594); AIg62 = A(F126-E227; D502-S594);
AIg63 = A(D228-H319; D502-S594); AIg64 = A(A320-Q408; D502-
S594); AIg6Fn1 = A(D502-S594; G604-P691); AIg6Fn2 = A(D502-
S594; T706-P807); AIg6Fn3 = A(D502-S594; K808-P908); AIg6Fn4 =
A(D502-S594; P907-G1001).
Transfection of COS-1 cells
Transient transfectants were obtained by electroporation according to
Chu et al. (1987) and Rols et al. (1994). In brief, 106 trypsinized COS-l
cells were resuspended in 700 ,tl of phosphate-buffered saline (PBS;
137 mM NaCI, pH 7.4, 3 mM KC1, 8 mM Na2HPO4, 1.5 mM KH2PO4)
and mixed with 100 .tl of PBS containing 10 ,ug of CsCI-purified vector
DNA. After a 10 min incubation on ice, electroporation was carried out
in a 1 cm cuvette by applying 960 gF and 230 V (Bio-Rad Gene Pulser).
Post-incubation was for 10 min at 37°C. Then, the cells were cultured
on 28 cm2 cell culture dishes in 5 ml of Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf serum (FCS) at
370C in 5% CO2. After 7 h, the cells were washed twice with PBS and
incubated overnight with 10 ml of DMEM, 10% FCS.
For immunoblotting the cells were washed twice with PBS and
detached by treatment with 2 mM EDTA in PBS 2 days after transfection.
For solubilization of membrane proteins, detached cells were sonicated
with 10 pulses (20 W. I s) using a microtip sonifier (Branson Sonic
Power Co., Danbury, CT). The membranes were sedimented by ultra-
centrifugation at 200 000 g for 20 min at 4°C and solubilized with
2% SDS. Immunoblotting was performed using 10 jil of solubilized
membranes corresponding to i104 COS cells per lane. For comparison,
5 jil of vitreous fluid of 14-day-old chicken embryos was blotted.
Immunodetection was carried out with mixtures of four mouse mono-
clonal antibodies against axonin-1 and goat anti-mouse IgG conjugated
to peroxidase (Kirkegaard & Perry Laboratories, Inc., Gaithersburg. MD)
at a dilution of 1:1000.
Binding of NgCAM-coated Covaspheres to transfected
COS-1 cells and immunofluorescence staining
One day after transfection, cells were washed twice with PBS. detached
by treatment with 2 mM EDTA in PBS, and resuspended in DMEM,
10% FCS. The cells were cultured overnight on polylysine-coated glass
Lab-Tek slides (Nunc Inc., Naperville. IL) at 37°C in 5% CO2. Two
days after transfection, the cells were washed twice with DMEM.
5 mg/ml bovine serum albumin (BSA). NgCAM-coated tetramethyl-
rhodamine isothiocyanate (TRITC) Covaspheres (Kuhn et al., 1991)
were sonicated for 2 min, diluted 1:1000 in DMEM, 5 mg/ml BSA and
again sonicated for 3 min immediately before use. The cells were
incubated with the prepared Covaspheres for I h at 37°C in 5%k
CO,. washed twice with DMEM, 5 mg/ml BSA, and fixed with 2%
formaldehyde (Fluka Chemie AG, Buchs, Switzerland) for I h at 37°C.
After washing twice with PBS, 1% FCS, axonin- I-expressing cells were
detected by indirect immunofluorescence staining using goat antiserum
raised against axonin- (1:l1000 dilution) and fluorescein isothiocyanate
(FITC)-conjugated rabbit anti-goat IgG (1:1)00 dilution; Zymed Labora-
tories Inc., South San Francisco, CA). The preparation was examined
with a fluorescence microscope (Leitz DMR: Leica AG, Heerbrugg,
Switzerland) using a G/R filter (Leica) for simultaneous detection of
FITC and TRITC fluorescence. For quantification, green fluorescing
cells binding at least three red fluorescing Covaspheres were scored as
binding cells (non-expressing cells were found to bind 0-1 Covaspheres)
and 100 cells were scored in all. In antibody blocking experiments, the
cells were pre-incubated for 2 h at 37°C with IgG of mouse monoclonal
or goat polyclonal antibodies at a concentration of 30 or 500 jIg/ml,
respectively, in DMEM, 1% FCS. Incubation with NgCAM-coated
TRITC Covaspheres and fixation was carried out as described above.
Axonin-l-expressing cells that had bound the antibodies were detected
by incubation with FITC-conjugated goat anti-mouse IgG (1:200 dilution;
Cappel; Organon Teknika nv, Turnhout. Belgium) or FITC-conjugated
rabbit anti-goat IgG (1:100 dilution; Zymed). respectively.
Myeloma-based production of soluble axonin- 1 variants
For wild-type-Ck, the cDNA fragment CR2F-HB3 was amplified by
PCR using the full-length axonin-l cDNA clone d-509 as a template
(Zuellig et al., 1992) and the primer pair CR2F (Rader et al., 1993)
and HB3 (5'-GCCAAGCTTACTTACCTCCACTGTTTCGGACGATG-
3'). PCR amplification was performed as previously described (Rader
et al., 1993). CR2F-HB3 was digested with HindIll and used to substitute
the HindIlI fragment of the axonin-I coding region in pMAX (Rader
et ail., 1993). This substitution fused the axonin-l coding region to the
exon encoding the Ig-K constant region (Ig CK). For a vector map of
pMAX which is derived from pCD4-FvCD3-C, (Traunecker et al..
1991b) see Rader et al. (1993).
For AIgl234-C, the axonin-I deletion mutant AIgl234 was cloned
into pMAX generating pMAX/AIg1234. HindIll-digested CR2F-HB3
was cloned into pMAX/Algl234 as described for wild-type-C,.
For IgI234-Ck, a Sad site was introduced at the Ig4/Ig5 border by
oligonucleotide-directed mutagenesis using pTZ19U/axS-H (see above)
as a template for the oligonucleotide CRS4 (5'-GCTGAATTAACA-
GTGGGAGCTCTAGCACCAGATTTTAG-3'). A Q408G amino acid
substitution resulted from the SacI insertion. The SacdI fragment that
encodes the start codon, the signal peptide and the four amino-terminal
Ig domains of axonin-I was cloned into Sacl-digested pMAX, thereby
substituting the entire axonin- 1 coding region and fusing the four amino-
terminal Ig domains to Ig C,.
The integrity of the three constructs was confirmed by double-strand
DNA sequencing. Stable transfectants were obtained by transfecting the
constructs into the mouse myeloma cell line J558L by protoplast fusion
(Oi et al., 1983). Selection and screening of transfected myeloma cells
was done as previously described (Rader et al.. 1993). For isolation of
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the axonin- variants. transfected myeloma cells were adapted to 1 %
FCS in DMEM and cultivated in roller bottles (Costar. Cambridge. MA).
Supernatants were concentrated by ultrafiltration (Skanette: Skan AG,
Basel. Switzerland) and passed through an immunoaffinity column with
immobilized rat anti-mouse C, mAb 187.1 (American Type Culture
Collection. Rock-ville. MD). Bound antigen was washed with 50 column
volumes of PBS and eluted w\ith 50 mM diethylamine. The eluate was
neutralized immediately by the addition of 1/5 volume I M Tris-HCI.
pH 7.0. and dialysed against PBS.
Neurite outgrowth assay
Native axonin- and axonin- variants at a concentration of 75 Pg/ml
were adsorbed directly to tissue culture plastic (Nunclon; Nunc) for 2 h
at 37°C. After washing with PBS. the tissue culture plastic was blocked
for 30 min at 37°C with 10 mg/ml ovalbumin and washed auain with
PBS. Dissociated dorsal root ganglion neurons from 10-day-old chicken
embryos were plated at a density of 70 000 cells/10 cm2 and cultivated
for 22 h in serum-free medium as specified previously (Stoeckli et al..
1991). For antibody perturbation tests. Fab of monoclonal mouse anti-
axonin- lG and Fab of polyclonal goat anti-axonin-I IgG were added
to a final concentration of 30 and 300 pg/ml. respectively. After 22 h in
culture, the cells were fixed by addition of glutaraldehyde to a final
concentration of 2cc. Quantification of neurite outgrowth was performed
as described by Venstrom and Reichardt (1995). Cells with neurites
longer than two cell body diameters were scored as cells with neurites
and 100 cells were scored for each condition.
Electron microscopy
Axonin-I molecules were adsorbed on glow-discharged C-coated EM
grids by placing the grids with the C-film facing down on 5 ,ul drops of
a 75 utg/ml dilution of native axonin-l in 20 mM NaP. pH 7.3. After
60 s. the excess liquid was removed and the immobilized molecules
stained for 30 s with two sequentially applied drops of 2C/% uranyl
acetate. Finally, excess stain was blotted off with filter paper. After air
drying. the grids were examined in a Philips CM 12 transmission electron
microscope operating at 100 kV acceleration voltage. Micrographs were
taken with a Gatan G94 Slow Scan CCD camera under low dose
conditions at a magnification of 60 000 and at -500 nm underfocus.
The images were stored on an Apple Macintosh Quadra 950 computer
and hard copies wvere made with a Tektronics IISD sublimation printer.
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